Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics
ITRM Price/Volume Stats
| Current price | $1.65 | 52-week high | $2.50 |
| Prev. close | $1.66 | 52-week low | $0.60 |
| Day low | $1.65 | Volume | 2,531 |
| Day high | $1.66 | Avg. volume | 78,782 |
| 50-day MA | $1.09 | Dividend yield | N/A |
| 200-day MA | $1.05 | Market Cap | 21.52M |
ITRM Stock Price Chart Interactive Chart >
Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.
Latest ITRM News From Around the Web
Below are the latest news stories about ITERUM THERAPEUTICS PLC that investors may wish to consider to help them evaluate ITRM as an investment opportunity.
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call TranscriptIterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Hello, everyone, and welcome to the Iterum Therapeutics Third Quarter 2023 Financial Results and Business Update. My name is Harry, and I’ll be your operator today. [Operator Instructions] And I will now hand the call over to Louise Barrett, Senior Vice President, […] |
Q3 2023 Iterum Therapeutics PLC Earnings CallQ3 2023 Iterum Therapeutics PLC Earnings Call |
Iterum Therapeutics Reports Third Quarter 2023 Financial Results-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ende |
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, November 14, 2023. Management will |
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections– Topline Data Expected in Early Q1 2024 – – NDA Resubmission Expected in Q2 2024 – DUBLIN, Ireland and CHICAGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the completion of patient enrollment in its REASSURE (REnewed ASsessment of Sulopene |
ITRM Price Returns
| 1-mo | 122.82% |
| 3-mo | 98.80% |
| 6-mo | 50.00% |
| 1-year | 41.03% |
| 3-year | -86.90% |
| 5-year | -98.61% |
| YTD | 96.43% |
| 2022 | -85.71% |
| 2021 | -60.38% |
| 2020 | -78.02% |
| 2019 | -10.18% |
| 2018 | N/A |
Continue Researching ITRM
Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...